Drawing for TOLERO PHARMACEUTICALS

USPTO serial 79212382

TOLERO PHARMACEUTICALS

Reviewed by CopyMark Law Group

Reg. 5505386Status 709
Filing date
Status date
Registration date
Jul 3, 2018
Examiner
FOSDICK, GEOFFREY A
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with TOLERO PHARMACEUTICALS?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Howard N. Aronson

Howard N. Aronson Lackenbach Siegel LLP1 Chase Rd.Lackenbach Siegel Bldg.Scarsdale, NY 10583-4156

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations, namely, anti-inflammatories; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the central nervous system, namely, diseases of the brain, movement, ocular motility and spinal cord diseases, encephalitis, epilepsy, Alzheimer's, cerebral palsy and Parkinson's disease and central nervous systems infections; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the peripheral nervous system, namely, amyotrophic lateral sclerosis, numbness, lightheadedness, dysuria and dyshidrosis; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the respiratory system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the urogenital system, namely, urological diseases, infertility, sexually transmitted diseases and inflammatory pelvic diseases; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the cardiovascular system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the endocrine system, namely, growth and thyroid disorders; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the metabolic system, namely, diabetes, hypoglycemia, gout, osteoarthritis, muscular dystrophy, anemia, bulimia nervosa, anorexia, obesity and hypothyroidism; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the renal system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the gastroenterological system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the ophthalmologic system; pharmaceutical preparations for the prevention and treatment of disorders and diseases of the dermatologic system, namely, dermatitis, eczema, psoriasis, skin pigmentation diseases and sexually transmitted diseases; pharmaceutical preparations for the prevention and treatment of hematologic and oncologic disorders and diseases; pharmaceutical preparations for the prevention and treatment of psychiatric disorders and diseases, namely, anxiety disorders, mood disorders, schizophrenia, cognitive and bipolar disorders, epilepsy, Parkinson's disease, Alzheimer's disease, cerebral palsy, multiple sclerosis and seizures; pharmaceutical preparations for the prevention and treatment of allergic disorders and diseases and disorders and diseases of the immune system, namely, autoimmune diseases and immunologic deficiency syndromes; pharmaceutical preparations for the prevention and treatment of connective tissue and joints, namely, connective tissue diseases, bone diseases, spinal diseases, back pain, fractures and cartilage injuries; pharmaceutical preparations for the prevention and treatment of cancer; pharmaceutical preparations for use in chemotherapySECTION 71 - CANCELLED—
044Providing medical informationSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Mar 19, 2026INNTTOTAL INVALIDATION PROCESSED BY THE IB—
Feb 28, 2026INTSTOTAL INVALIDATION OF REG EXT PROTECTION SENT TO IB—
Feb 28, 2026INPCINVALIDATION PROCESSED—
Sep 17, 2025INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
Jan 17, 2025C71TCANCELLED SECTION 71—
Jul 3, 2023REM3COURTESY REMINDER - SEC. 71 (6-YR) E-MAILED—
Oct 26, 2018FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 4, 2018FICSFINAL DISPOSITION NOTICE SENT TO IB—
Oct 4, 2018FIMPFINAL DISPOSITION PROCESSED—
Oct 3, 2018FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Jul 3, 2018R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Apr 17, 2018NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
Apr 17, 2018PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 13, 2018GPNXNOTIFICATION PROCESSED BY IB—
Mar 28, 2018OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Mar 28, 2018NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Mar 28, 2018OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Mar 15, 2018CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 14, 2018TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Mar 13, 2018CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Mar 13, 2018TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Dec 22, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 22, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 22, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Dec 19, 2017TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Dec 19, 2017CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Dec 15, 2017ALIEASSIGNED TO LIE—
Dec 7, 2017TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 8, 2017ARAAATTORNEY/DOM.REP.REVOKED AND/OR APPOINTEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Nov 8, 2017REAPTEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED—
Aug 12, 2017RFNTREFUSAL PROCESSED BY IB—
Jul 27, 2017RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Jul 27, 2017RFRRREFUSAL PROCESSED BY MPU—
Jul 25, 2017MAFRAPPLICATION FILING RECEIPT MAILED—
Jul 21, 2017RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Jul 20, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 19, 2017DOCKASSIGNED TO EXAMINER—
Jul 19, 2017NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jul 14, 2017LIMILIMITATION FROM ORIGINAL APPLICATION ENTERED—
Jul 13, 2017REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance